Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Clinical yield and utility of germline multigene panel testing across hereditary cancer syndromes: A systematic review of real-world evidence.

Mansi Mody, Hem prajapati, Rishi Sravan Kilari et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22664

e22664 Background: Germline multigene panel testing (MGPT) is widely used for hereditary cancer risk assessment , but real...

Early mortality and hospitalization following cholangiocarcinoma diagnosis by statin exposure: A TriNetX real-world analysis.

Reshma John, Aqsa Zoey Sorathia, Divya Samat et al. Jun 01, 2026 pp. 11195-11195 10.1200/jco.2026.44.16_suppl.11195

11195 Background: Statins are widely prescribed among patients with cardiometabolic comorbidities and are frequently conti...

Low-dose radiation therapy for peripheral joint osteoarthritis: Early U.S. community experience with pain, function, and medication outcomes.

Emily Schwartz, Michael J. Anderson, Russell Nevins et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24051

e24051 Background: Osteoarthritis (OA) causes progressive pain and disability, yet non-surgical options are limited for pa...

Real-world experience with tarlatamab in extensive-stage small cell lung cancer at an academic center in Mississippi.

Adil Mohyudin, Bobby Se, Grace Shumaker et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20156

e20156 Background: Small cell lung cancer (SCLC) has poor outcomes, and patients from underserved rural and minority popul...

Longer-term safety of pimicotinib in tenosynovial giant cell tumor (TGCT): Integrated analysis of phase 1 and phase 3 MANEUVER trial data.

Hans Gelderblom, Vinod Ravi, Vishal Ghori et al. Jun 01, 2026 pp. 11568-11568 10.1200/jco.2026.44.16_suppl.11568

11568 Background: TGCT is a rare, locally-aggressive neoplasm associated with significant morbidity and functional impairm...

Chemotherapy (CT) use by Oncotype DX (O-Dx) recurrence score (RS) in hormone receptor–positive, HER2-negative (HR+/HER2-) invasive lobular carcinoma (ILC): A contemporary National Cancer Database (NCDB) analysis.

Marija Sullivan, Xiudong Lei, Inimfon Jackson et al. Jun 01, 2026 pp. 531-531 10.1200/jco.2026.44.16_suppl.531

531 Background: ILC has a distinct biology and is considered less chemosensitive than invasive ductal carcinoma (IDC). O-D...

Transposable elements and homotypic niches as drivers of immune dynamics and resistance in melanoma epigenetic-based immunotherapy.

Teresa Maria Rosaria Maria Rosaria Noviello, Erika Ciervo, Francesco Ceccarelli et al. Jun 01, 2026 pp. 9531-9531 10.1200/jco.2026.44.16_suppl.9531

9531 Background: Melanoma plasticity facilitates immune evasion and therapy resistance through dynamic cell-state transiti...

Cancer survivorship care plans: Patients, needs, benefits—retrospective analysis.

Wael Lasheen, Declan Walsh, Wei Sha et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13793

e13793 Background: Survivorship care plans (SCPs) are designed to address the needs of cancer survivors transitioning from...

Awareness of breast cancer symptoms and risk factors among urban Delhi women.

Shrey Chopra, Sukul Khanna, Arihant Senthil et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24102

e24102 Background: Breast cancer is the most frequently diagnosed malignancy among Indian women, and late presentation con...

Expansion of circulating NKG7⁺ cytotoxic CD4⁺ T cells as a predictor of response to PD-1 blockade in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective phase II study with translational analysis.

Chang Gon Kim, Jaehyung Kim, Moonki Hong et al. Jun 01, 2026 pp. 6043-6043 10.1200/jco.2026.44.16_suppl.6043

6043 Background: Nivolumab has demonstrated meaningful survival benefit in patients with refractory R/M HNSCC. Nevertheles...

Prophylactic vedolizumab to facilitate use of immune-checkpoint inhibitors in cancer patients at high risk of immune-mediated colitis.

Hemant Khandelia, David Hockenbery, Daniel S. Hippe et al. Jun 01, 2026 pp. 12134-12134 10.1200/jco.2026.44.16_suppl.12134

12134 Background: Inflammatory diarrhea/colitis is a frequent immune-related adverse event (IRAE) associated with immune c...

Association of inpatient mortality and resource utilization with acute complications among colorectal cancer hospitalizations in the United States.

Michael Ghobrial, Faizan Sheraz, Arash Latifi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23220

e23220 Background: Hospitalization for colorectal cancer (CRC) is frequently complicated by acute clinical events. Nationa...

Impact of tumor site and diagnostic pathway on stage at diagnosis: A population-based study of 5,638 salivary gland cancer patients (2013–2023).

Samuel Rack, Guy Betts, Sian Dobbs et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18140

e18140 Background: Salivary gland cancer (SGC) are rare and heterogeneous malignancies. Delays in diagnosis are common and...

Clinical and genomic characterization of de novo prostate cancer presenting with PSA ≥100 ng/mL.

Tara Al-Saleem, Ann Tierney, Miles Hsu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17024

e17024 Background: In the era of PSA screening for prostate cancer, presentation with PSA ≥100 ng/mL is rare. We sought to...

Baseline phosphoproteomic signatures in peripheral blood and prediction of durable response to CAR T-cell therapy in B-cell malignancies.

Christian A. Gordillo, Weronika E. Borek, Federico Pedicona et al. Jun 01, 2026 pp. 7038-7038 10.1200/jco.2026.44.16_suppl.7038

7038 Background: Despite the success of Chimeric Antigen Receptor (CAR) T-cell therapy, most patients fail to achieve dura...

Multimodality neoadjuvant downstaging therapy before liver transplantation for colorectal liver metastasis: Real-world data from the Cleveland Clinic.

Mazhar Khalil, Chase Wehrle, Ahmed Sayed Ahmed et al. Jun 01, 2026 pp. 3594-3594 10.1200/jco.2026.44.16_suppl.3594

3594 Background: Liver transplantation (LT) has a clear survival benefit in advanced, unresectable, liver-confined colorec...

Comprehensive profiling of EGFR PACC mutations and their co-mutation landscape in Chinese patients with non–small cell lung cancer: A large-scale NGS study of 2,360 cases.

Yuan Jiang, Mingyue Lin Jun 01, 2026 pp. 8650-8650 10.1200/jco.2026.44.16_suppl.8650

8650 Background: EGFR PACC (P-loop and αC-helix compressing) mutations represent a group of noncanonical alterations locat...

Allostatic load as a mediator of exposomic risk pathways to early-onset cancer: A cross-cohort validation study.

Ravi Bharat Parikh, Anthony Girard, Tyler M. Moore et al. Jun 01, 2026 pp. 10500-10500 10.1200/jco.2026.44.16_suppl.10500

10500 Background: Early-onset cancer (EoC, defined as any solid tumor diagnosed ≤50 years age) incidence has incre...

Alternative splicing signatures to predict response from hyperthermic intra-peritoneal chemotherapy (HIPEC) treatment in ovarian cancer patients.

Thanh Hue Dellinger, Nathaniel P. Hansen, Ritin Sharma et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17576

e17576 Background: HIPEC is associated with improved survival in epithelial ovarian cancer (EOC) patients, but no predicti...

Integration of a diabetes practitioner in breast cancer care and its impact on glucose management.

Andrew Horvit, Uma Gunasekaran Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23064

e23064 Background: Dysglycemia in breast cancer patients is associated with poor cancer outcomes and increased emergency d...

Safety and reliability of isatuximab subcutaneous on-body injector: Results across the phase 3 IRAKLIA, phase 2 IZALCO and phase 1b TCD15484 trials.

Xavier P. Leleu, Claudio Cerchione, Sikander Ailawadhi et al. Jun 01, 2026 pp. 7563-7563 10.1200/jco.2026.44.16_suppl.7563

7563 Background: Subcutaneous (SC) drug delivery options have become more widely available in multiple myeloma (MM). SC de...

A novel ultra-low 6-month PSA cutoff for radiographic PFS stratification in high-volume mHSPC.

Fatih Kemik, Cevat İlteriş Kıkılı, Buğra Han Esen et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17099

e17099 Background: In metastatic hormone-sensitive prostate cancer (mHSPC), a 6-month PSA nadir ≤0.2 ng/mL is commonly app...

Comparative serious safety reporting signals for antibody-drug conjugates versus HER2-targeted non-ADC therapies: A FAERS analysis (2020–2025).

Reshma L. Mahtani, Zouina Sarfraz, Naomi Dempsey et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13084

e13084 Background: Antibody–drug conjugates (ADCs) have transformed systemic cancer therapy but are associated with distin...

Indirect calorimetry and estimated energy prescription in hospitalized cancer patients.

Diogo Toledo, Gabriel Bernardes Yacoub, Gustavo Schvartsman et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23335

e23335 Background: Indirect calorimetry is recommended as the reference method for individualized energy prescription in p...

A phase II, multicenter, single-arm clinical trial of response-adapted definitive radiotherapy and cemiplimab-rwlc immunotherapy for locally advanced, unresectable cutaneous squamous cell carcinoma: RAMPART.

Christopher Andrew Barker, Ryan Michael Lanning, Shlomo A. Koyfman et al. Jun 01, 2026 pp. 9506-9506 10.1200/jco.2026.44.16_suppl.9506

9506 Background: Locally advanced (T3-4/N+/M0) and unresectable cutaneous squamous cell carcinoma (LAUCSCC) patients (pts)...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page